The cryogenic medicine team of our hospital won the 25th invention patent
Recently, the Cryomedicine Center of Shandong Yinfeng Life Sciences Research Institute (the research unit of our foundation) once again obtained the invention patent for "a placental tissue matrix material and its preparation method". Up to now, the total number of patent authorizations granted by the cryogenic medicine team from the State Intellectual Property Office has reached 25.
The patent was officially submitted on November 25, 2019, and it took two years until the patent certificate was approved. The patent discloses a placenta tissue matrix material, which is a special scaffold material containing active cytokine receptors prepared from placenta tissue. It can actively attract active ingredients in the living body into the material, causing the accumulation of active cell ingredients to support cells. Attachment, infiltrative growth, proliferation and differentiation.
The repair and reconstruction of tissues and organs has always been a research hotspot in the fields of tissue engineering, biology, and medicine. With the development of technology, tissue engineering products have gradually become clinically important surgical repairs and substitutes, and have become the mainstay of current clinical surgical treatments. It is an important treatment measure for the loss of human tissue and organs and various injuries caused by accidents and other accidents. Tissue engineering materials can be said to be the basis for the research and development of this product, and are expected to become the first choice for surgical repair and replacement in clinical practice.
At present, most tissue engineering materials use natural polymer materials that can provide bioactive components as their main components, such as collagen, gelatin, hyaluronic acid, chitosan, etc. However, these traditional tissue engineering materials have insufficient biomechanical strength and are inconsistent with the body. There are deficiencies such as poor tissue integration and mismatch between degradation rate and tissue reconstruction. Therefore, the use of decellularization technology to remove cells and DNA that cause immune responses in tissues to obtain extracellular matrix (ECM) as a biomaterial stands out in tissue engineering research.
However, although some products of domestic acellular tissue matrix (ACTM) materials have entered preclinical trials, they are mostly derived from animal collagen such as pigs and cattle. They are not only expensive, have limited clinical use effects, but also have potential Risks of infection and immune rejection, and due to the diverse surgical and clinical needs, tissue engineering products of different specifications, different scales and multiple structural and activity requirements are required, which are difficult to meet with conventional extracellular matrices and scaffolds.
To this end, Yinfeng Low Temperature Center invented and provided a medical biomaterial prepared from human placenta tissue - placenta tissue matrix material. The placental tissue matrix material of the present invention does not contain immune antigens of allogeneic tissue, retains receptors for multiple active factors in the extracellular matrix of the placental tissue, and has various forms (such as particles, gels and porous scaffolds). The placenta tissue matrix material of the present invention can be implanted into tissue defects and wounds in the body, helps accumulate active cell components, supports cell migration, attachment, proliferation and differentiation, accelerates the repair of damaged tissues, and can meet the needs of different parts and shapes. clinical needs.
Yinfeng Cryogenic Medicine Center will work hard to accelerate technological innovation, promote the transformation of results, and promote the early application of the acellular matrix obtained by this invention in the fields of burns and plastic surgery, medical cosmetology, diabetic foot, etc., and become an important surgical repair for clinically treating diseases and saving lives. and alternatives, for human health.
On August 23, the Jinan Private Economic Development Bureau and China Economic Weekly jointly launched the theme publicity activity of "Central Media Look at Jinan - Entering Jinan's Private Economy" in Yinfeng Biotechnology Park.
Led by Anhui Medical University and participated by Yinfeng Cryogenic Medical Technology Co., Ltd., the "Engineering Research Center for Life Resources Conservation and Artificial Organs of the Ministry of Education" was officially accepted and awarded by the Ministry of Education. As one of the four major platforms for the transformation of the center's project, Yinfeng Cryogenic Co., Ltd. is responsible for the "development, promotion and application of cryogenic preservation technology of biological matrix materials".
On March 28, 2023, the kick-off meeting of the International Alliance for Life Extension Research was held in Jinan, Shandong. The "International Alliance for Life Extension Research" was initiated by Shandong Yinfeng Life Science Research Institute, and jointly established by 13 international scientific research institutions engaged in the field of cryogenic biomedicine from North America, Europe, Oceania, etc., and appeared at the conference through online and offline forms.